Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NL-OMON27630Not yet recruiting
Open-label, single-arm trial of entecavir and tenofovir in Chronic Hepatitis B (CHB), sponsored by Erasmus MC. Primary endpoint: Sustained response at week 48. Planned start Sep 2017; status: not yet recruiting.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on NL-OMON27630.